Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: Results from the U-ACHIEVE phase 3 maintenance trial

被引：0

作者：

Feagan, Brian ^{[1
]}

Parkes, Gareth ^{[2
,3
]}

Juillerat, Pascal ^{[4
,5
]}

Gecse, Krisztina ^{[6
]}

Yao, Xuan ^{[7
]}

Zhou, Wen ^{[7
]}

Deng, Huiwen ^{[7
,8
]}

Ilo, Dapo ^{[7
]}

Gonzalez, Yuri Sanchez ^{[7
]}

Higgins, Peter D. R. ^{[9
]}

机构：

[1] Western Univ, Div Gastroenterol, London, ON, Canada

[2] Barts Hlth NHS Trust, London, England

[3] Barts & London Queen Marys Sch Med & Dent, London, England

[4] Inselspital Bern, Dept Visceral Surg & Med, Gastroenterol, Bern, Switzerland

[5] Bern Univ, Bern, Switzerland

[6] Amsterdam UMC, Locat AMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[7] AbbVie Inc, Chicago, IL USA

[8] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA

[9] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA

来源：

SWISS MEDICAL WEEKLY | 2023年 / 153卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IBD-1

引用

页码：2S / 2S

页数：1

共 33 条

[21] Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: Results from the Phase 3 U-ACHIEVE maintenance trial
Parkes, G.
Ungaro, R.
Danese, S.
Abreu, M.
Arenson, E.
Zhou, W.
Ilo, D.
Laroux, S.
Deng, H.
Gonzalez, Y. S.
Peyrin-Biroulet, L.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 157 - 157
[22] Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial
Parkes, G.
Ungaro, R.
Danese, S.
Abreu, M.
Arenson, E.
Zhou, W.
Ilo, D.
Laroux, F. S.
Deng, H.
Gonzalez, Y. Sanchez
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I476 - I477
[23] Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
Panes, Julian
Loftus, Edward, V
Higgins, Peter D. R.
Lindsay, James O.
Zhou, Wen
Yao, Xuan
Ilo, Dapo
Phillips, Charles
Tran, Jacinda
Sanchez Gonzalez, Yuri
Vermeire, Severine
INFLAMMATORY BOWEL DISEASES, 2023, : 1421 - 1430
[24] Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE
Higgins, Peter
Hebuterne, Xavier
Siffledeen, Jesse
Zhou, Wen
Cataldi, Fabio
Xie, Wangang
Lacerda, Ana
Danese, Silvio
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S131 - S131
[25] EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B STUDY U-ACHIEVE
Panaccione, Remo
D'Haens, Geert R.
Sandborn, William J.
Ghosh, Subrata
Schreiber, Stefan
Tanida, Satoshi
Zhou, Wen
Cataldi, Fabio
Pugatch, David
Huang, Bidan
Xie, Wangang
Higgins, Peter D.
GASTROENTEROLOGY, 2019, 156 (06) : S170 - S170
[26] ECONOMIC IMPACT OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE CROHN'S DISEASE AND ULCERATIVE COLITIS: INDUCTION AND MAINTENANCE PHASE 3 RESULTS ON WORK PRODUCTIVITY LOSS
Yu, T.
Dulai, P. S.
Griffith, J.
Sharma, D.
Loftus, E., V
VALUE IN HEALTH, 2024, 27 (06) : S131 - S132
[27] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Danese, Silvio
Vermeire, Severine
Zhou, Wen
Pangan, Aileen L.
Siffledeen, Jesse
Greenbloom, Susan
Hebuterne, Xavier
D'Haens, Geert
Nakase, Hiroshi
Panes, Julian
Higgins, Peter D. R.
Juillerat, Pascal
Lindsay, James O.
Loftus, Edward V., Jr.
Sandborn, William J.
Reinisch, Walter
Chen, Min-Hu
Gonzalez, Yuri Sanchez
Huang, Bidan
Xie, Wangang
Liu, John
Weinreich, Michael A.
Panaccione, Remo
LANCET, 2022, 399 (10341): : 2113 - 2128
[28] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Vermeire, S.
Danese, S.
Zhou, W.
Pangan, A.
Greenbloom, S.
D'Haens, G.
Panes, J.
Juillerat, P.
Lindsay, J. O.
Loftus, E. V., Jr.
Sandborn, W. J.
Reinisch, W.
Gonzalez, Y. Sanchez
Huang, B.
Xie, W.
Liu, J.
Weinreich, M. A.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
[29] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Pangan, Aileen
Greenbloom, Susan
D'Haens, Geert
Panes, Julian
Juillerat, Pascal
Lindsay, James
Loftus, Edward V.
Sandborn, William
Reinisch, Walter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
[30] Effect of Upadacitinib Treatment on Hematological Parameters in Patients With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis: Pooled Analysis of Phase 3 Induction and Maintenance Studies
Dubinsky, Marla
Regueiro, Miguel D.
Ha, Christina
Melmed, Gil Y.
Armuzzi, Alessandro
Irving, Peter M.
Anyanwu, Samuel
Dubcenco, Elena
Aponte, Fernando
Shah, Isheeta
Wang, Tao
Suravaram, Smitha
Palac, Hannah
Rubin, David T.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S765 - S766

← 1 2 3 4 →